Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2019 Financial Results and Business Updates
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 4593947. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to cancer patients. Mersana’s lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Investor & Media Contact
Source: Mersana Therapeutics, Inc.